OBJECTIVES: According to the relevant clinical trial in patients having reoperations with cardiac resynchronization therapy with a defibrillator or pacemaker, the use of Tyrx^TM was associated with a 47% lower risk of major and minor device-related infections due to cardiac implantable electronic devices within a 24-month period. The study aimed to conduct cost-consequences analysis of Tyrx^TM antibacterial envelope therapy compared to standard care for infection control in high-risk patients undergoing device replacement procedures in Türkiye, from the perspective of the Social Security Institution (SGK), the national reimbursement agency.

METHODS: A cost-consequences analysis was performed, taking into account direct costs. The total medical device costs that patients had anticipated to fully claim within the SGK reimbursement scope were considered. Clinical data (infection rates, mortality rates and prophylactic antibiotic use rates) for the study were obtained from expert opinions and a literature review, and data on costs were obtained from the Health Implementation Communiqué (SUT).

RESULTS: The analysis revealed that the total cost of using Tyrx^TM was TRY68,553 compared to TRY41,604 for standard care. Comparing the infection costs, 24-month costs for Tyrx^TM were found to be TRY33,950 and for standard care, TRY7,063. The lifetime cost was TRY34,602 for Tyrx^TM and TRY34,541 for standard care.

CONCLUSIONS: The TYRX absorbable antibacterial envelope promotes faster and smoother healing, reducing inflammation and forming a thin, even capsule. This could make follow-up procedures easier if needed. Despite its higher cost, TYRX treatment offers significant clinical benefits by lowering the risk of infection, which is associated with a threefold higher mortality risk. Therefore, it is recommended that Tyrx^TM be considered as a treatment option for high-risk patients, leading to potential reimbursement by the SGK based on the evaluation of relevant experts.